Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
GLUE submitted a Form 144 notice reporting planned and recent transactions in Common Stock. The notice lists 2,176 shares associated with an exercise of stock options and a proposed sale on 06/17/2026 for cash. It also discloses prior sales by Jennifer Champoux of 2,176 shares on 05/22/2026 and 2,175 shares on 05/27/2026, with reported amounts of $41,344.00 and $43,500.00, respectively.
Monte Rosa Therapeutics director Ali Behbahani received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual stockholder meeting, subject to his continued service.
Monte Rosa Therapeutics director Andrew N. Schiff received a grant of stock options for 25,800 shares of common stock. The options have an exercise price of $17.10 per share and were awarded as compensation, not through open-market buying or selling.
The options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options covering 25,800 underlying shares directly.
Monte Rosa Therapeutics director Anthony M. Manning received a grant of stock options for 25,800 shares of Common Stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, provided he continues in service until that time. Following this grant, he holds 25,800 derivative securities representing rights to acquire common shares.
Monte Rosa Therapeutics director Jan Skvarka received a grant of 25,800 stock options for common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. Following this grant, he holds options for 25,800 shares. The options vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as he continues serving the company.
Monte Rosa Therapeutics director Kimberly Blackwell received a grant of stock options on Common Stock. The award covers 25,800 options, each with an exercise price of $17.10 per share, giving her the right to buy an equal number of shares in the future.
These options vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, as long as she continues serving until that time. After this grant, she holds 25,800 derivative securities from this award, which expire on June 11, 2036 if not exercised.
Monte Rosa Therapeutics director Eric A. Hughes received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. This is a compensation-related equity award, not an open-market purchase.
All 25,800 options will vest and become exercisable in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to his continued service. Following this grant, Hughes holds 25,800 stock options directly.
Monte Rosa Therapeutics director Christine Siu received a grant of stock options covering 25,800 shares of common stock. The options have an exercise price of $17.10 per share and expire on June 11, 2036. They vest in full on the earlier of June 11, 2027 or the company’s next annual meeting of stockholders, subject to her continued service.
Monte Rosa Therapeutics held its 2026 annual stockholder meeting, where investors voted on board elections and the company’s auditor. As of the April 16, 2026 record date, there were 84,382,573 shares of common stock outstanding.
Stockholders elected three Class II directors to serve until the 2029 annual meeting. Andrew Schiff, M.D. received 71,409,008 votes for and 741,197 withheld; Chandra P. Leo, M.D. received 71,469,933 votes for and 680,272 withheld; and Anthony Manning, Ph.D. received 56,995,916 votes for and 15,154,289 withheld. Each director election also had 3,128,885 broker non-votes.
Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 75,171,524 votes for, 57,950 against, 49,616 abstentions and no broker non-votes. No other matters were submitted for a vote at the meeting.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported open-market sales of a total of 5,466 shares of common stock on June 1, 2026. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, at weighted average prices around the high-$18 to high-$19 range.